{"data":{"id":"us-in/ic-27-8-14.3-3","jurisdiction":"us-in","citation":"IC 27-8-14.3-3","heading":"\"Biomarker\"","body":"Sec. 3. (a) As used in this chapter, \"biomarker\" means a characteristic that is objectively measured and evaluated as an indicator of:\n(1) normal biological processes;\n(2) pathogenic processes; or\n(3) pharmacologic responses to a specific therapeutic intervention, including known gene-drug interactions for medications being considered for use or already being administered.\n(b) The term includes gene mutations, characteristics of genes, and protein expression.","path":["TITLE 27. INSURANCE","ARTICLE 8. LIFE, ACCIDENT, AND HEALTH","Chapter 14.3. Coverage for Biomarker Testing"],"source_url":"https://iga.in.gov/ic/2026/Title_27.html#27-8-14.3-3","current_through":"2026","vintage":"2026","retrieved_at":"2026-09-25T05:39:04Z","sha256":"33f048fb73cd55c68ddb23e8dc5f806df563ae66023c5a774881098823084724","source_id":"us-in","stale":false,"prev":"us-in/ic-27-8-14.3-2","next":"us-in/ic-27-8-14.3-4"},"notice":"GroundRules: Original legal text. Not legal advice."}